Clinical Trial Update: Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study [Phase 2]

View source ↗

Summary

A Phase II dose-confirmation study of the Clostridioides difficile vaccine candidate VLA84 in adults 50 and older evaluated immunogenicity and safety, with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• VLA84 (VLA84 vaccine)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Clostridium Difficile | Phase 2 | Status: COMPLETED | Results posted: 2017-06-08